Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Moreover, while traditional approaches use mice that have been genetically modified to produce human antibodies, these antibodies are not completely encoded by human genes and are, therefore, not ...

Discover how AAV-based gene therapy delivers anti-eosinophil antibodies, offering hope for chronic hypereosinophilia ...

Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

“Our unique RenMice ® platform enables the discovery of fully human antibodies with high affinity, low immunogenicity, and favorable developability. With Adcendo’s extensive expertise in ...

This approach reduces immunogenicity without hindering the antigen-binding site. Fully human antibodies can be generated via phage display technology or from human B cells. These antibodies are ...

GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted ...

Data were summarized with the search of 'colorectal' and 'antibody' as of August 2012 at ClinicalTrials.gov [202]. EGFR: EGF receptor; mAb: Monoclonal antibody; VEGFR: VEGF receptor. The authors ...

Adcendo exercises its option to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need This collaboration further validates ...